Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(20%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
4
40%
Ph phase_4
1
10%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1
Enrolling by invitation1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 41 (12.5%)

Trials by Status

completed660%
withdrawn110%
enrolling_by_invitation110%
recruiting110%
active_not_recruiting110%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruiting

Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study

NCT05393388
enrolling_by_invitationphase_2

Tau PET Outcomes With Anti-amyloid Immunotherapies

NCT06723015
recruitingphase_2

PET Tau - Neurodegenerative Disease Imaging

NCT03143374
completedphase_1

Tau PET Imaging in Atypical Dementias

NCT03283449
completedphase_4

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

NCT04417998
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05393388

Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study

Active Not Recruiting
NCT06723015Phase 2

Tau PET Outcomes With Anti-amyloid Immunotherapies

Enrolling By Invitation
NCT03143374Phase 2

PET Tau - Neurodegenerative Disease Imaging

Recruiting
NCT03283449Phase 1

Tau PET Imaging in Atypical Dementias

Completed
NCT04417998Phase 4

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

Completed
NCT02850146Phase 1

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

Completed
NCT04080544Phase 2

Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Completed
NCT03287765

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

Completed
NCT02676843Phase 2

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Completed
NCT02512029Phase 1

18F-AV-1451 PET Imaging in TBI

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10